FTRACK
ftrack , the developer of Academy Award-winning media review and team collaboration solutions for the creative industries, has launched significant updates to two of its flagship offerings: ftrack Review , the browser-based platform for interactive media review, and cineSync , the desktop media review solution heavily utilized by the film and television industries. ftrack Review’s new free-flowing user experience makes for a more lightweight, accessible media review experience for creatives, while cineSync’s fundamental update addresses the evolving needs of VFX studios working today.
Both ftrack Review’s reimagined workflows and cineSync 5 are available to try today. cineSync 5 is available as a free extension for all cineSync 4 Pro users.
ftrack was recently acquired by Backlight, a media technology company serving media, entertainment and video-forward customers with technology solutions that dramatically improve every step of the media content lifecycle. The acquisition allows ftrack to focus on product development and innovation, and provide its customers with the best possible tools and solutions like ftrack Review and cineSync.
ftrack Review Reimagined
ftrack Review introduces a newly updated, modern user interface designed for highly intuitive, user-friendly review sessions, alongside a greater focus on efficiency.
“We’ve listened to our customers’ feedback and have incorporated it into a new ftrack Review update that makes for a more responsive media review experience,” says Rory McGregor, product manager. “Users can now benefit from everything they enjoyed before—including centralized feedback cycles and interactive real-time review—but with the added advantage of a much more effortless workflow. We’re excited to see what our users think as we advance our multifaceted media review ecosystem at ftrack.”
Some of the new features in ftrack Review include:
- An all-new interface designed to make reviews more free-flowing
- Faster, more streamlined and responsive reviews with fewer clicks, even when reviewing larger projects with lots of guests and notes
- A newly designed feedback bar
- New toolbar features like ghosting, flip and flop, and resolution selection
- New features for the power user, including tools to manage reviews from within the player interface.
See the complete list of features in ftrack Review’s latest update
ftrack Review's new features are planned to be implemented into ftrack Studio soon—ftrack's full production tracking, shot management, and media review platform
"The latest update to ftrack Review shows that ftrack has listened to our needs and quickly implemented much-valued new features,” says John Valentine, ftrack/workflow coordinator at Blue Zoo Animation Studio, an animation studio known for producing children's television series, advertising commercials, and short films. “With a new, user-friendly UI, an intuitive design layout, and more emphasis on what's being reviewed, it has never been easier for ourselves or our clients to view, comment and review material, we at Blue Zoo are excited by what we've seen and what's coming next."
Introducing cineSync 5
cineSync 5 is built on the legacy of industry-leading cineSync, now reimagined and rebuilt from the ground up to meet the evolving demands of creative review and approval. cineSync 5 streamlines the media review process and supports more collaborative reviews—both local and remote—while still meeting the highest requirements across security and performance that cineSync users have come to expect over the last 17 years.
Some of the new features in cineSync 5 include:
- A new infrastructure designed to support faster, more responsive reviews
- Local review without a license via cineSync Play
- OTIO and OCIO v2 support
- Frame/image sequence playback and OpenEXR support
- Enhanced production tracking integrations with ftrack Studio and ShotGrid
- Localization support
- A new, modern UI
See the complete list of features in cineSync 5
“We’re excited to share cineSync 5 with our cineSync Pro users so they can get a first taste of the future of cineSync,” says Rory McGregor, product manager. “We’ve improved performance, added new features and workflows, updated our sync servers, and redesigned the UI. With these new features, we’re ushering in a new generation for cineSync—one that will make our users’ collaborative workflows more productive than ever before.”
“cineSync 5 is a significant upgrade on an application that's already the best in class. The killer news was the totally overhauled comparison tool with single-key access to shots, interactive and customizable wipe-line, and 0-100% cross-fades,” said Jake Morrison, VFX supervisor, Thor Love & Thunder . “Bonus points for being able to drag anywhere in the window to scrub back and forth with just a hotkey. I never knew I needed it, but now I use it all the time! Congrats to the cineSync team for an outstanding update to an already indispensable tool. They've clearly listened to their users – every new feature feels like it adds functionality. Grab it!”
Ftrack will showcase cineSync5 and the new ftrack Review later this month at the NAB Show in Las Vegas from April 23 to April 27.
About ftrack
ftrack, a Backlight business, is the creator of ftrack Studio, cineSync, and ftrack Review, the Emmy and Academy Award-winning production tracking, interactive media review, and team collaboration platforms for the creative industries. ftrack’s solutions are designed for producers, supervisors, artists, and pipeline developers and make it easy to seamlessly and securely collaborate with anyone, anywhere. Both ftrack's products and company ethos are founded on the core belief that success results from great teamwork. ftrack has built a talented global team that works with honesty, flexibility, and inclusivity and seeks to build a future where process disappears behind progress. ftrack was founded in 2012 and acquired by Backlight in 2021. ftrack is celebrating its 10th anniversary in 2022. To learn how ftrack is helping creatives meet the ever-increasing demands of creative workflows, please visit ftrack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom